Merrimack Pharmaceuticals Inc (NASDAQ:MACK) announced its second quarter 2016 financial results. ONIVYDE® (irinotecan liposome injection) Update ONIVYDE updates include: Receipt of positive opinion …
Merrimack Pharmaceuticals Inc (NASDAQ:MACK) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a …
Merrimack Pharmaceuticals Inc (NASDAQ:MACK) announced a newly presented analysis of the Phase 3 NAPOLI-1 data shows patients treated with ONIVYDE® (irinotecan liposome injection), also …
Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) announced results from the final analysis of the Phase 1 study of MM-151, a novel investigational oligoclonal epidermal growth factor …
Anavex Life Sciences Corp. Anavex Life Sciences Corp.
Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) announced the initiation of a biomarker-selected, multi-arm Phase 1 clinical study in metastatic colorectal, non-small cell lung, and head and …
Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced its first quarter 2016 financial results.
Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) announced positive data from preclinical studies evaluating MM-310, an antibody directed nanotherapeutic (ADN) that encapsulates a newly engineered form …
Biotech earnings season continues with Horizon Pharma PLC (NASDAQ:HZNP) reporting fourth-quarter results on Monday, while Merrimack Pharmaceuticals Inc (NASDAQ:MACK) reported earnings yesterday after closing. Let’s …
Biotechnology companies are kicking of pipeline trials for 2016. Analysts weigh in on Merrimack Pharmaceuticals Inc (NASDAQ:MACK) and Egalet Corp (NASDAQ:EGLT) in light …
